Successful Rechallenge with Imatinib in a Patient with Chronic Myeloid Leukemia Who Previously Experienced Imatinib Mesylate Induced Pneumonitis / 결핵및호흡기질환
Tuberculosis and Respiratory Diseases
;
: 256-259, 2013.
Article
in English
| WPRIM
| ID: wpr-194718
ABSTRACT
Imatinib mesylate is a targeted therapy that acts by inhibiting tyrosine kinase of the bcr-abl fusion oncoprotein, which is specific to chronic myeloid leukemia (CML), and the c-transmembrane receptor, which is specific to gastrointestinal stromal tumors. Interstitial pneumonitis is a rare adverse event of imatinib therapy. It is clinically difficult to distinguish from infectious pneumonia, which can frequently occur due to the underlying disease. The standard treatment for imatinib-induced pneumonitis is to discontinue the medication and optionally administer corticosteroids. However, there are a few cases of successful retrial with imatinib. We describe a case of successful rechallenge of imatinib in a patient with imatinib-induced interstitial pneumonitis and CML without a recurrence of the underlying disease after 3 months of follow-up.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pneumonia
/
Recurrence
/
Protein-Tyrosine Kinases
/
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/
Follow-Up Studies
/
Adrenal Cortex Hormones
/
Lung Diseases, Interstitial
/
Mesylates
/
Gastrointestinal Stromal Tumors
/
Imatinib Mesylate
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Tuberculosis and Respiratory Diseases
Year:
2013
Type:
Article
Similar
MEDLINE
...
LILACS
LIS